The advisors of ATB Therapeutics on 54 million euros Series A financing

Baker McKenzie has advised ATB Therapeutics, a Belgian next-generation antibody company, on the successful closing of a 54 million euros Series A financing. With this financing, ATB Therapeutics will advance the development of oncology and immunology drug candidates based on its patented ATBioFarm platform. The financing was led by EQT Life Sciences, alongside the wider syndicate of investors including, among other, V-Bio Ventures, the Belgian Wealth Sovereign Fund SFPIM, VIVES Partners, Wallonie Entreprendre and Sambrinvest.

Berthold Hummel (PICTURED), partner of Baker McKenzie from Munich’s office, also advised on the deal together with Younes Sebbarh (senior associate, Brussels, lead lawyer), Roel Meers (partner, Brussels), Tine Torfs (associate, Brussels), Jean de Limburg Stirum (associate, Brussels), Brian Gielen (associate), Elvin Lawson (associate, Brussels), Emilien Lerouge (associate, Brussels), and Veerle Lerut (of counsel, Brussels).

“Thanks to our team of specialized corporate/M&A and life sciences lawyers, we were able to contribute on the legal side to the success of this Series A financing round of ATB Therapeutics. This will further expand the potential of the ATBioFarm platform and make transformative therapies available to patients worldwide”, commented Younes Sebbarh.

Founded in 2018, ATB Therapeutics is a biotechnology company based in Marche-en-Famenne, Belgium, specializing in the discovery and development of novel antibody therapies. Utilizing a proprietary technology platform based on plant-based molecular farming, ATB Therapeutics aims to deliver targeted solutions for oncology and autoimmune diseases through innovative next-generation antibody therapies.